It is safe to administer antifibrotic drugs to patients with idiopathic pulmonary fibrosis, possibly reducing disease progression over time in those awaiting lung transplant, according to recent study results.

“With increasing use of antifibrotics following recent FDA approval, questions arise about their safety in idiopathic pulmonary fibrosis (IPF) patients undergoing lung transplant, yet safety data in this specific setting are currently lacking,” Isabelle Delanote, MD, from the department of respiratory disease at the University Hospitals Leuven in Belgium, and colleagues wrote. “Moreover, it is unclear whether antifibrotic treatment, when effectively achieving disease stabilization for several months, would influence lung allocation score or may even interfere with referral for lung transplant.”

In a single-center retrospective cohort analysis, the researchers assessed pretransplant pulmonary function, functional exercise capacity, and immediate and long-term post-operative outcomes to report on the safety and efficacy of antifibrotics in patients with IPF undergoing lung transplant.

Categories

Disclaimer

The Alliance shares recent articles from credible media sources for informational and professional discussion purposes. We claim no authorship of such content, nor does it necessarily reflect the views of this organization.